BioNTech Stopped an mRNA Cancer Vaccine Trial After a Survival Imbalance

BioNTech and Genentech ended a Phase 2 colorectal-cancer trial after an independent board found an overall-survival imbalance and judged further study unlikely to show benefit. The size and direction of that imbalance remain undisclosed, and the board reported no new safety signal tied to the vaccine.